LCTX vs MTNB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LCTX Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while MTNB counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus MTNB at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against MTNB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LCTX Revenue | MTNB Revenue | LCTX Op. Margin | MTNB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $0M | -837.9% | -12230.9% | LCTX |
| FY2019 | $0M | $0M | -1106.0% | -21067.4% | LCTX |
| FY2020 | $0M | $0M | -1448.4% | -15288.4% | LCTX |
| FY2021 | $0M | $0M | -1133.6% | -74954.5% | LCTX |
| FY2022 | $10M | $0M | -153.2% | -771.3% | LCTX |
| FY2023 | $10M | $0M | -276.5% | -2168.4% | LCTX |
| FY2024 | $10M | N/A | -226.1% | N/A | LCTX |
| FY2025 | $10M | N/A | -251.6% | N/A | LCTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LCTX | MTNB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $212.1M | $979,904 | Larger Scale | LCTX |
| Trailing P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | 30.7x | N/M | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | -61.0% | -100.0% | Higher Growth | LCTX |
| Operating Margin (TTM) Profitability | -280.3% | 0.0% | Higher Margin | MTNB |
| Net Profit Margin Profitability | 16.2% | 0.0% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | 4.3% | -147.5% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 4% ($1โ$2) | 22% ($0โ$3) | Stronger Trend | MTNB |
| Beta / 30D Volatility Risk Regime | 1.36ฮฒ ยท 79% Vol | -7.20ฮฒ ยท 147% Vol | Lower Realized Risk | LCTX |
| Unified Institutional Score Composite Signal | 58.9 / 100 (HOLD) | 54.6 / 100 (HOLD) | Higher Composite | LCTX |